Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply

Aliment Pharmacol Ther. 2021 Mar;53(5):642-643. doi: 10.1111/apt.16241.

Sara Rundquist¹, Michael C Sachs², Carl Eriksson^{1

2}, Ola Olén^{2

3}, Scott Montgomery^{2

4}, Jonas Halfvarson¹

¹ Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
² Epidemiology Division, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
³ Sachs' Children and Youth Hospital, Department of Clinical Science and Education, Stockholm South General Hospital, Karolinska Institute, Stockholm, Sweden.
⁴ Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden.

No abstract available

Publication types